力朴素与奈达伯联合先期化疗对晚期卵巢上皮性癌的临床观察

目的观察力朴素与奈达伯联合行新辅助化疗对晚期卵巢上皮性癌近期的疗效及毒副反应。方法晚期卵巢上皮性癌80例，采用力朴素与奈达伯联合化疗方案（力朴素135mg／m2，奈达伯80mg／m2-100mg／m2），全身静脉化疗结合腹腔灌注化疗，3周为一个疗程，于术前完成1—2个疗程治疗后，行体检、影像学检查及手术治疗，从而判断治疗疗效及毒副作用。结果治疗有效率为92．5％（74／80）；白细胞下降发生率为50％（40／80），胃肠道反应发生率为77．5％（62／80）；所有患者均未因毒副反应中断或退出治疗。结论力朴素与奈达伯联合行先期化疗对晚期卵巢上皮性癌效果较好，毒副反应较轻。

A clinical observation on neoadjuvant chemotherapy for ovary tumor of advanced stage treated with paclitaxel liposome and nedaplatin

Objective To study the therapeutic effect and side effects of combined therapy with paclitaxel liposome and Nedaplatin on advanced ovary cancer.Methods 80 cases of ovary cancer with advanced stage were studied.A combined chemotherapy of paclitaxel liposome and Nedaplatin were applied.The dose of paclitaxel liposome was 135mg/m2 with Nedaplatin 80mg/m2-100mg/m2.The total course of treatment were three weeks,all cases finish at least 1-2 course of treatment.Results The bone marrow depression incidence was 50%,Gastrointestinal tract reaction rate was 77.5% No patient exit the therapy because of side effects.Conclusions The combined therapy of paclitaxel liposome and NDP showed good efficacy accompanied by less side effects.